Together these results suggested that doxorubicin causes nuclear relocation of FOXO3a in the drug sensitive breast cancer cells, and confirmed our previous data that FOXO3a expression is predominantly nuclear in the resistant cells. The gene discussed is FOXO3; the disease is breast carcinoma.